1. Human angiotensin-converting enzyme from kidney, lung, small intestine, plasma and urine was found to be immunologically indistinguishable by double immunodiffusion and inhibition of enzyme activity with specific anti-(human kidney enzyme) antibody.
Introduction
Angiotensin-converting enzyme (ACE; EC 3.4.15.1) converts angiotensin I into angiotensin I1 and inactivates bradykinin by releasing the C-terminal dipeptide [ 11. In 1979 an orally active inhibitor of this enzyme, captopril, was shown to effectively reduce blood pressure in hypertensive Correspondence: Professor Tatsuo Kokubu, The 2nd Department of Internal Medicine, Ehime University School of Medicine, Onsen-gun, Ehime 79 1-02, Japan.
patients [2] . This compound when administered orally reaches ACE and inhibits the conversion 'of angiotensin I and the inactivation of bradykinin in viva The lung is a rich source of ACE [31 and thought to be the most important site for the inhibitor. However, ACE is known to occur in several other tissues and fluids 131. We therefore investigated the immunological properties of ACE preparation from human tissues and fluids, including kidney, lung, small intestine, plasma and urine, and the distribution of ACE in human tissues by an immunofluorescent method.
Materials and methods
ACE was solubilized from human kidney cortex with trypsin and purified to homogeneity [41. Purification procedures included fractionation with DEAE-cellulose, hydroxyapatite and DEAE-Sephadex A-50, preparative isoeletric focusing and gel filtration on Sephadex G-200. The purified ACE had a specific activity of 96.0 pmol min-I mg-I of protein for hippuryl-histidylleucine (Hip-His-Leu). Human lung and small intestinal ACE preparations that were solubilized with trypsin, and plasma and urinary enzyme preparations, were partially purified by DEAEcellulose and hydroxyapatite column chromatography under the same conditions as the purification method used for human kidney ACE. Plasma and urinary ACE were followed by an additional purification by gel filtration on Sephadex G-200. The specific activities of the partially purified ACE were: 1.94 units/mg for lung, 1-28 units/mg for small intestine, 0.86 unit/mg for plasma and 0.67 unit/mg for urine. These ACE preparations were similarly inhibited by captopril and activated by chloride ion. ACE activity was measured by a modified method of Cushman & Cheung 151. The assay mixture contained borate/sodium carbonate (0-1 mol/l, pH 8.3), NaCl (0.8 mol/l), Hip-His-Leu (3.5 mmol/l) and various amounts of the enzyme. One unit of ACE activity was defined as the amount of the enzyme catalysing the release of 1 pmol of hippuric acid from Hip-His-Leu per rnin at 37OC. Protein was determined by the method of Lowry et al. [61, bovine serum albumin being used as standard.
The antibody to human kidney ACE was raised in two rabbits by intradermal injections of 500 pg of the purified enzyme in sodium phosphate solution (10 mmol/l, pH 7.2) containing NaCl (1 50 mmol/l) (phosphate-buffered saline) emulsified with equal volume of Freund's complete adjuvant (Difco, U.S.A.) three times at 20 days interval. Immunoglobulin G (IgG) fractions of immune serum and serum taken before immunization from the same rabbits were purified by ammonium sulphate fractionation and DEAE-cellulose column chromatography [7, 81. Recovery of IgG was monitored by assaying fractions for their inhibitory effect on ACE activity. Antibody proteins were estimated by absorbance at 280 nm (1.40 litre g-' cm-I). The purified IgG fraction from the immune serum gave a single precipitin band with the purified and crude ACE of human kidney on double immunodiffusion by the method of Ouchterlony [91. Apparently normal adult human tissue specimens (kidney, lung and small intestine) were obtained at surgical operations from cancerous patients, then immediately frozen and stored at -80°C. Frozen sections with thickness of 4-6 pm were air-dried, fixed with cold acetone for 2 rnin and washed in phosphate-buffered saline for 20 min. Thereafter, the tissue sections were incubated for 30 rnin with dilutions (1 : 20) of the purified IgG fraction from the immune serum on glass slides at room temperature. In controls, the purified IgG fraction from the preimmune serum of the same rabbit and the immune IgG fraction absorbed by ACE until no inhibitory effect on ACE activity remained were used in this step. After washing in phosphate-buffered saline for 30 min, the sections were stained for 30 min with dilutions (1 : 10) of fluorescein-labelled goat anti-(rabbit immunoglobulin) (Behringwerke AG, W. Germany), which had been absorbed by rat liver acetone-dried homogenate to prevent non-specific staining, washed again in phosphate-buffered saline for 40 min, and then mounted in buffered glycerol (pH 7.2). The stained sections were examined with a fluorescence microscope (Zeiss, Universal type, W. Germany) with the use of BP 450-490 exciter filter and BP 520-560 barrier filter.
Results
After incubation with various amounts (0-100 pg) of the antibody (IgG) for 30 min in phosphate-buffered saline, the remainig ACE activities were measured with Hip-His-Leu under the standard conditions. The antibody (10 pg) inhibited more than 50% of catalytic activity of 0.2 unit of the purified and crude human kidney ACE preparations. The antibody also showed closely similar titration curves against ACE activities of human lung, small intestine, plasma and urine. However, only a partial cross-reactivity with the antibody was observed against rat, hog and dog serum ACE. When incubated with 10 pg of the antibody, no inhibitory effect on these ACE activities was found, and 100 pg of the antibody inhibited 20% of ACE activity of hog (0.11 unit), 10% of dog (0.06 unit), and 16% of rat serum (0.09 unit). Serum ACE activities of sheep and bovine were not inhibited at all, even if 100 pg of the antibody were added to the reaction mixture. The antibodies from two separately immunized rabbits yielded comparable results.
Immunodiffusion analysis was performed with human kidney, lung, small intestine, plasma and urine ACE preparations. These enzymes gave a single precipitin band and completely crossreacted against anti-(human kidney ACE) antiserum (Fig. la) .
In immunofluorescent localization, the kidney displayed specific intense fluorescence in the epithelial cells of proximal tubules and linear fluorescence along Bowman's capsule. However, no fluorescence was present in the distal tubules and glomerular capillary network (Fig. lb) . The lung showed fluorescence along the alveolar wall (Fig. lc) , and on the luminal side of interstitial small vessels. With higher magnification the fluorescence was located in the vascular endothelial cells. The bronchi did not show any staining. In the small intestine, fluorescence was seen in the epithelial cells of the mucous membrane (Fig. Id) .
Discussion
Our results indicate that human ACE preparations from kidney, lung, small intestine, plasma and urine had immunologically common cross-reacting determinants, which differed in extent and specificity from serum ACE of five other mammals. Rabbit antibody to human kidney ACE had only a partial cross-reactivity with serum ACE from hog, dog and rat by the anticatalytic activity, and had no cross-reactivity with those from sheep and bovine. Similar immunological homology in individuals has been demonstrated in rabbit, with the exception of seminal plasma [lo] , and in hog [ill. Partial cross-reactivity with lung ACE among several species has been also shown [ 121. These findings and our data suggest that antigenic determinants of ACE may be variable from species to species, but not in each individual.
Immunofluorescent study of human ACE confirmed the previous reports with animals [13-161 that ACE was localized in two types of cells: these were the vascular endothelial cells in the lung and the epithelial cells in the kidney and small intestine. Inhibition of ACE by the orally active specific inhibitor captopril may take place first in the epithelial cells of small intestine, and then in the endothelial cells of lung or other tissues, resulting in lowering of elevated blood pressure. Blockade of kidney ACE in the proximal tubular cells may interfere with the degradation of angiotensins and kinins after glomerular filtration and, thereby, may affect the renin-angiotensin and kallikrein-kinin systems in the kidney.
